Discovery of non-LBD inhibitor for androgen receptor by structure-guide design.
Bioorg Med Chem Lett
; 23(13): 3887-90, 2013 Jul 01.
Article
en En
| MEDLINE
| ID: mdl-23727044
ABSTRACT
In this study, we synthesized the BF-3 binding small molecules, a series of pyridazinone-based compounds, as a novel class of non-LBP antiandrogens for treating prostate cancer by inhibiting androgen receptor. The new class compound was discovered to inhibitor the viability of AR-dependent human prostate LNCap cells and AR activity combining with the computational method. It showed a good physicochemical and PK property.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Neoplasias de la Próstata
/
Piridazinas
/
Receptores Androgénicos
/
Descubrimiento de Drogas
/
Antineoplásicos
Límite:
Animals
/
Humans
/
Male
Idioma:
En
Revista:
Bioorg Med Chem Lett
Asunto de la revista:
BIOQUIMICA
/
QUIMICA
Año:
2013
Tipo del documento:
Article